Back to first-pass browser

First-pass extracted concept

Selective MT2 receptor ligands

Candidate: concept label1 source documents4 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This concept refers to ligands that selectively engage MT2 receptors. In the review abstract, MT2 activation is associated with selective increases in NREM sleep.

Source 1DOIPubMed

Resources required

Use requires subtype-selective MT2 pharmacology and sleep phenotyping methods capable of resolving NREM outcomes.

Source 1DOIPubMed

What problem it solves

Selective MT2 ligands help distinguish NREM-promoting MT2 effects from MT1-linked REM and circadian effects.

Source 1DOIPubMed

What it does not solve

The abstract does not establish a specific clinical product or provide detailed implementation data for any one MT2 ligand.

Source 1DOIPubMed

Alternatives

The review contrasts selective MT2 ligands with melatonin and non-selective MT1/MT2 agonists, which are described as having modest hypnotic effects.

Source 1DOIPubMed

Evidence Snippets

Recent advancements using selective MT1/ MT2 receptor ligands and MT1/MT2 receptor knockout mice have suggested that the activation of the MT2 receptors selectively increase non-REM (NREM) sleep.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1anatomical localization summarysupports2019Source 1DOIPubMed

The review states that MT2 receptors are located in the reticular thalamus, whereas MT1 receptors are located in the locus coeruleus and lateral hypothalamus, consistent with distinct NREM and REM associations.

Claim 2circadian function summarysupports2019Source 1DOIPubMed

The review suggests that MT1, but not MT2, receptors appear to be involved in regulation of circadian rhythm.

Claim 3functional specializationsupports2019Source 1DOIPubMed

The review supports that MT1 receptor activation is mainly implicated in REM sleep regulation, whereas MT2 receptor activation selectively increases NREM sleep.

Claim 4therapeutic potential summarysupports2019Source 1DOIPubMed

The review suggests that selective MT2 agonists or partial agonists may have therapeutic potential for NREM-related sleep or anxiety disorders, whereas selective MT1 agonists or partial agonists may have therapeutic potential for REM-related sleep disorders.